Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand

• Eli Lilly CEO expects new weight loss pill to be approved next year

  Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.
  
  CNBC - 1d

• Eli Lilly strikes deal for cancer treatment, gives timeline for weight loss pill

  Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
  
  CNBC - 1d

• High cost of weight loss drugs drives employers to require nutrition counseling, in boost for startups

  Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss management program.
  
  CNBC - 4d

• Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says

  It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss.
  
  CNBC - 5d
• 

  Weight-loss drugs like Ozempic may be up for Medicare price negotiations — will Trump support it?

  Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face an uncertain future in the incoming Trump administration.
  
  NBC News - 5d
• 

  Smith dumps Diageo stake over impact of weight-loss drugs on alcohol demand

  Veteran stockpicker sells shares in spirits brand because drinks sector is being ‘impacted negatively’
  
  Financial Times - 5d

• Eli Lilly's lead in the obesity race has grown. Its recent stock performance says otherwise

  Eli Lilly has been one of the worst-performing Club stocks over the past six months.
  
  CNBC - 6d

• Drug Company to Share Revenues With Indigenous People Who Donated Their Genes

  Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes.
  
  The New York Times - Jan. 7
• 

  Pharma giant seeks to join lawsuit against FDA over weight loss drugs

  Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the "entitlement" some ...
  
  The Hill - Jan. 2

More from CNBC

• Meta announces 5% cuts in preparation for 'intense year' — read the internal memo

  Meta will cut about 5% of its staff, focusing on its lowest-performing workers, CNBC confirmed.
  
  CNBC - 2h

• Microsoft pauses hiring in U.S. consulting unit as part of cost-cutting plan, memo says

  Microsoft plans to pause hiring in part of its consulting business in the U.S., according to an internal memo, as the company seeks ways to reel in expenses.
  
  CNBC - 3h

• Intel to spin off venture capital arm as chipmaker continues to restructure

  Intel said Tuesday that it plans to spin off Intel Capital, its venture capital wing, into an independent firm.
  
  CNBC - 2h

• Budget deficit rose in December and is now 40% higher than it was a year ago

  For the final calendar month of 2024, the shortfall totaled $86.7 billion, which actually represented a 33% decline from a year prior.
  
  CNBC - 5h

• Trump says he'll create 'External Revenue Service' to collect tariffs, foreign revenue

  President-elect Donald Trump has reportedly contemplated declaring a national economic emergency to implement tariffs.
  
  CNBC - 3h

More in Business

• This is Nvidia’s secret weapon and it’s likely to propel the stock in 2025

  Strength in data center GPUs, networking, services, and emerging products fortify Nvidia’s competitive ‘moat.’
  
  MarketWatch - 11m

• Companies are expected to post their best earnings growth in 3 years. The biggest gains won’t come from Big Tech.

  Financials should be the biggest profit gainers this earnings season — but as Trump returns, trends could be “much more volatile than Trump 1.0,” analyst says.
  
  MarketWatch - 14m

• SEC lawsuit against Elon Musk is a big political test for Trump administration

  Trump appointee Paul Atkins is set to face a major minefield upon taking over leadership of the SEC, given Musk’s close ties to the incoming president.
  
  MarketWatch - 19m
• 

  Trump Pentagon pick Hegseth nears US Senate approval after testy hearing

  Former Fox News host claims ‘smear campaign’ sought to halt his nomination, but he appears likely to secure votes
  
  Financial Times - 1h

• ‘I’ve never been happier’: I married a wonderful lady from Ukraine. I have two successful kids. Do I put my wife on the deed to my home?

  “We are now looking to downsize and move to another home and I’m wondering if we should put the new property in joint names.”
  
  MarketWatch - 1h